Galectin Therapeutics is a clinical-stage biopharmaceutical company focused entirely on developing belapectin (GR-MD-02), a galectin-3 inhibitor derived from plant-based pectin and administered intravenously. Galectin-3 is a protein involved in fibrosis and tumor immune suppression. Galectin Therapeutics' primary target is MASH cirrhosis — specifically, preventing esophageal varices in patients with portal hypertension, a condition with no currently approved treatments. Belapectin's lead trial, NAVIGATE, produced mixed results: the primary intent-to-treat analysis did not reach statistical significance, but a pre-specified per-protocol subgroup showed a statistically significant 49.3% reduction in varices incidence, and U.S. patients showed a 68.1% reduction. The company's path forward — FDA submission, a confirmatory trial, or a partnership — remains unresolved. Galectin Therapeutics also has an early-stage oncology program exploring belapectin in combination with checkpoint inhibitors for head and neck cancer, though this program depends on securing a partner or financing before advancing. The company has nine full-time employees and outsources all manufacturing, clinical operations, and research. Galectin Therapeutics has no product revenue and funds operations entirely through equity financing. Its strategy is to advance belapectin to value-inflection points and then seek a larger pharmaceutical partner for commercialization, rather than building out its own commercial infrastructure. Galectin Therapeutics also holds a majority stake in Galectin Sciences, a joint venture developing oral small-molecule galectin-3 inhibitors.